Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder
Nature Medicine, Published online: 20 November 2026; doi:10.1038/s41591-026-04781-0 Concerns about use of placebo control in clinical trials of Obinutuzumab β for aquaporin-4 antibody positive neuromyelitis optica spectrum disorder
Read the full story at Nature Medicine ↗
ImpactMinor
Published20 h ago (Fri, 20 Nov 2026 00:00:00 GMT)
AuthorElias S. Sotirchos
MoreLess
Impact score6/100
RatingProbability of 88%.
RegionsGlobal
Retrievedvia rdf
ClassifiedFri, 20 Nov 2026 11:01:52 GMT by classifier